XML 41 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
The Company (Details)
3 Months Ended 9 Months Ended
Dec. 31, 2022
USD ($)
$ / shares
Sep. 30, 2022
USD ($)
product
Segment
$ / shares
Jan. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
Oct. 31, 2020
USD ($)
Sep. 30, 2019
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Line Items]            
Number of operating segments | Segment   1        
Number of FDA approved products | product   2        
Deferred revenue, non-current   $ 70,881,000   $ 64,315,000    
Total cash, cash equivalents and investments, fair value   $ 172,464,000   $ 139,801,000    
Common stock, par value (in dollars per share) | $ / shares   $ 0.001   $ 0.001    
Lyon Merger Sub, Inc            
Organization, Consolidation and Presentation of Financial Statements [Line Items]            
Professional services and other transaction costs   $ 10,400,000        
Lyon Merger Sub, Inc | Forecast            
Organization, Consolidation and Presentation of Financial Statements [Line Items]            
Common stock, par value (in dollars per share) | $ / shares $ 0.001          
Converted right to receivable (in dollars per share) | $ / shares $ 15.25          
Termination fee $ 27,000,000          
Payment on termination of merger agreement $ 65,000,000          
Second Santen Agreement | License Revenue, Upfront Payment            
Organization, Consolidation and Presentation of Financial Statements [Line Items]            
Deferred revenue, non-current     $ 90,000,000 $ 88,000,000 $ 50,000,000  
Second Santen Agreement | License Revenue, Additional Upfront Paymet            
Organization, Consolidation and Presentation of Financial Statements [Line Items]            
Deferred revenue, non-current       2,000,000    
Convertible Senior Notes            
Organization, Consolidation and Presentation of Financial Statements [Line Items]            
Principal amount           $ 316,250,000
Interest rate           1.50%
Convertible Senior Notes Due 2024 | Convertible Senior Notes            
Organization, Consolidation and Presentation of Financial Statements [Line Items]            
Principal amount   $ 316,250,000   $ 316,250,000   $ 316,250,000
Interest rate           1.50%